T 0594/24 (Pharmaceutical composition for modified-release/ASTELLAS) of 21.04.2026
- European Case Law Identifier
- ECLI:EP:BA:2026:T059424.20260421
- Date of decision
- 21 April 2026
- Case number
- T 0594/24
- Online on
- 25 June 2026
- Petition for review of
- -
- Application number
- 09817723.1
- IPC class
- A61P 13/10A61K 47/34A61K 47/18A61K 47/32A61K 47/26A61K 47/14A61K 47/10A61P 3/10A61K 47/02A61K 31/426A61K 47/22A61K 47/38A61K 47/12
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE
- Applicant name
- Astellas Pharma Inc.
- Opponent name
- Sandoz AG
Bülle Dr., Jan
Hamm&Wittkopp Patentanwälte PartmbB
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi
Teva Pharmaceutical Industries Ltd
Brand Murray Fuller LLP
DEVA HOLDING ANONIM SIRKETI - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- Rules of procedure of the Boards of Appeal Art 12(4)RPBA2020_Art_012(6)_(2020)_Sent_2Rules of procedure of the Boards of Appeal Art 13(2)European Patent Convention Art 100(a)European Patent Convention Art 56
- Keywords
- Amendment to case - (no)
Late-filed new submissions - admitted (no)
Admittance of late-filed evidences
Grounds for opposition - lack of inventive step (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.